Clinical data | |
---|---|
Other names | ADI-PEG20 |
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
UNII | |
ChEMBL |
Pegargiminase (also know as pegylated arginine deiminase) is an investigational drug used in arginine deprivation therapy for treating cancers deficient in argininosuccinate synthetase 1 (ASS1). [1] [2] [3] [4] It is a recombinant form of the enzyme arginine deiminase cloned from the bacteria Mycoplasma hominus and synthesized in Escherichia coli. It has been pegylated to improve the half-life and reduce immunogenicity. [1]
Clinical data | |
---|---|
Other names | ADI-PEG20 |
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
UNII | |
ChEMBL |
Pegargiminase (also know as pegylated arginine deiminase) is an investigational drug used in arginine deprivation therapy for treating cancers deficient in argininosuccinate synthetase 1 (ASS1). [1] [2] [3] [4] It is a recombinant form of the enzyme arginine deiminase cloned from the bacteria Mycoplasma hominus and synthesized in Escherichia coli. It has been pegylated to improve the half-life and reduce immunogenicity. [1]